Key result
ApoB/ApoA-I ratio reveals critically high atherogenic risk in CHD patients despite borderline traditional LDL-C.
Why the study?
The study aimed to evaluate the diagnostic utility of the apolipoprotein B to apolipoprotein A-I ratio compared to traditional LDL-C for risk stratification in comorbid patients with coronary heart disease.
Does the apolipoprotein B/A-I ratio provide superior risk stratification compared to traditional LDL-C in patients with chronic coronary syndromes?
Observational (n=210)
Does the apolipoprotein B/A-I ratio provide superior risk stratification compared to traditional LDL-C in patients with chronic coronary syndromes?
The apo-B/apo-A-I ratio may be a superior tool for identifying high residual cardiovascular risk in CHD patients who appear to be at borderline risk based on traditional LDL-C levels.
Hypothesis-generating for apo-B/apo-A-I in residual risk assessment; leaves open prospective validation before clinical adoption in chronic coronary syndromes.
This research aims to provide a comprehensive evaluation of the diagnostic utility of the apolipoprotein B (apo-B) to apolipoprotein A-I (apo-A-I) ratio as a superior risk stratification tool compared to traditional LDL-C in comorbid patients with coronary heart disease (CHD). 210 patients with functional class II-III exertional angina were examined. Results demonstrated that while standard lipidogram values (LDL-C 3.6 ± 0.1 mmol/l) classified patients as "borderline" risk, the apolipoprotein ratio (1.31 ± 0.01) revealed a critically high atherogenic potential. A significant influence of subclinical hypothyroidism (28.1% in women) and obesity on the formation of pathological apolipoprotein profiles was established. The study concludes that integrating apolipoprotein screening is essential for accurately determining residual cardiovascular risk and optimizing preventive therapy in regional clinical practice.
No takes yet. Share an insight, caveat, or question.
Virmani et al. (2026) conducted an observational in Coronary heart disease (CHD) with functional class II-III exertional angina (n=210). Apolipoprotein B/A-I ratio vs. Traditional LDL-C was evaluated on Atherogenic potential / risk stratification. The apolipoprotein B/A-I ratio (mean 1.31) revealed critically high atherogenic potential in CHD patients compared to borderline risk classification by traditional LDL-C (mean 3.6 mmol/l).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: